Technical Analysis for ONTX - Onconova Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 4.16 -0.72% -0.03
ONTX closed down 0.72 percent on Tuesday, March 19, 2019, on 83 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Mar 26

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ONTX trend table...

Date Alert Name Type % Chg
Mar 19 Calm After Storm Range Contraction 0.00%
Mar 19 Stochastic Reached Overbought Strength 0.00%
Mar 19 Upper Bollinger Band Walk Strength 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 19 BB Squeeze Ended Range Expansion 0.00%
Mar 19 Above Upper BB Strength 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Upper Bollinger Band Touch Strength 0.00%
Mar 18 MACD Bullish Signal Line Cross Bullish -0.72%
Mar 18 New Uptrend Bullish -0.72%

Older signals for ONTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its products include Rigosertib intravenous (IV) that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); Rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and Rigosertib IV, a combination therapy with gemcitabine in a Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer. The company's products also comprise ON 013105 that is in Phase I clinical trials to treat various lymphomas and leukemias; and Recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Biopharmaceutical Cancer Alpha Chemical Compounds Organic Compounds Radiation Myelodysplastic Syndrome Pyridines Tyrosine Kinase Inhibitors Bemcentinib Lymphomas Protein Kinase Inhibitors Head And Neck Cancers Leukemias Metastatic Pancreatic Cancer Heterocyclic Compounds Kinase Piperazines
Is ONTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.75
52 Week Low 1.69
Average Volume 144,509
200-Day Moving Average 5.1742
50-Day Moving Average 3.0965
20-Day Moving Average 3.6845
10-Day Moving Average 3.716
Average True Range 0.2852
ADX 26.62
+DI 27.3379
-DI 10.6955
Chandelier Exit (Long, 3 ATRs ) 3.4644
Chandelier Exit (Short, 3 ATRs ) 4.0456
Upper Bollinger Band 4.1122
Lower Bollinger Band 3.2568
Percent B (%b) 1.06
BandWidth 23.216176
MACD Line 0.2144
MACD Signal Line 0.1786
MACD Histogram 0.0358
Fundamentals Value
Market Cap 40.97 Million
Num Shares 9.85 Million
EPS -2.57
Price-to-Earnings (P/E) Ratio -1.62
Price-to-Sales 9.36
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.64
Resistance 3 (R3) 4.61 4.42 4.56
Resistance 2 (R2) 4.42 4.30 4.43 4.53
Resistance 1 (R1) 4.29 4.22 4.35 4.32 4.50
Pivot Point 4.10 4.10 4.13 4.11 4.10
Support 1 (S1) 3.97 3.98 4.04 4.00 3.82
Support 2 (S2) 3.78 3.90 3.80 3.79
Support 3 (S3) 3.65 3.78 3.76
Support 4 (S4) 3.68